2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãß°èÇмú´ëȸ

2024³â ´ëÇÑ°©»ó¼±ÇÐȸ Ãß°èÇмú´ëȸ°¡ Áö³­ 2024³â 8¿ù 30ÀϺÎÅÍ 31ÀϱîÁö ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÄÁº¥¼Ç¼¾ÅÍ¿¡¼­ ÁøÇàµÇ¾ú´Ù. À¯³­È÷ ´õ¿ü´ø À۳⠿©¸§ÀÇ ´õÀ§°¡ °¡½ÃÁö ¾ÊÀº ³¯¾¾¿¡ °¡À»ÇÐȸ°¡ °³ÃֵǾúÁö¸¸ Áö¼ÓµÇ´Â ÀÇÁ¤»çÅ¿¡µµ ºÒ±¸ÇÏ°í ¸¹Àº ȸ¿øµéÀÌ Âü¿©ÇÏ¿© ¼ºÈ²¸®¿¡ ÇмúÇà»ç°¡ ÁøÇàµÇ¾ú´Ù.


ù°³¯ °­¿¬¿¡¼­´Â Thyroid Hormone and Fertility ÁÖÁ¦·Î ³»°ú ¹× »êºÎÀΰú ¿¬ÀںеéÀ» ÃÊûÇÏ¿© ´ÙÇÐÁ¦ÀûÀÎ Á¢±Ù¿¡ ´ëÇÑ °­¿¬À¸·Î ½ÃÀÛÇÏ¿´À¸¸ç Medullary Thyroid Cancer¿¡ ´ëÇÑ ³»¿Ü°úÀû ÃֽŠÁö°ßÀ» ´Ù·ç´Â ¼¼¼ÇÀÌ À̾îÁ³´Ù.

ƯÈ÷ Meet the Professor1 ¼¼¼Ç¿¡¼­ ¿À·£¸¸¿¡ Gregory A. Brent (David Geffen School of Medicine at UCLA, USA) ±³¼ö°¡ Çѱ¹À» ¹æ¹®ÇÏ¿© °­¿¬À» ÇÏ¿´À¸¸ç µ¿ ½Ã°£´ë¿¡ Meet the Professor2 ¼¼¼Ç¿¡¼­ 20 Year Experience in Thyroid Intervention¶ó´Â Á¦¸ñÀ¸·Î ¿ï»êÀÇ´ë ¹éÁ¤È¯ ±³¼ö°¡ °­¿¬ÇÏ¿´À¸¸ç ±×µ¿¾È ½×¾Æ¿Â ÀÓ»ó °æÇè°ú ¿¬±¸ ¾÷ÀûÀ» ȸ¿øµé°ú °øÀ¯ÇÏ´Â ÀÚ¸®°¡ µÇ¾ú´Ù.



¿¬±¸À§¿øȸ¼¼¼Ç¿¡¼­´Â ¡°°©»ó¼± Áúȯ ´Ù±â°ü ¹«ÀÛÀ§¹èÁ¤ Àӻ󿬱¸ÀÇ ¹æ¹ý·Ð°ú ½ÇÁ¦¡±¶ó´Â ÁÖÁ¦·Î ÇöÀç ÁøÇàµÇ´Â °©»ó¼±ºÐ¾ßÀÇ RCT »ç¾÷À» ¼Ò°³ÇÏ°í ÇâÈÄ ¿¬±¸ÀÇ È°¼ºÈ­¸¦ À§ÇÑ ¹æ¹ý·Ð¿¡ °üÇÏ¿© ±íÀÌ ÀÖ´Â Åä·ÐÀÌ À̾îÁ³´Ù.

ÇÐȸ µÑ° ³¯ Gregory A. Brent ±³¼öÀÇ plenary lecture°¡ ÀÖ¾úÀ¸¸ç ±×µ¿¾ÈÀÇ ¿À·£ ÇмúÀûÀÎ ¼ºÃë¿Í ÇÔ²² Çѱ¹°úÀÇ °³ÀÎÀûÀÎ Àο¬ ¹× °¡Á·»ç¿¡ ´ëÇؼ­ ¼Ò°³ÇÏ´Â ÈÆÈÆÇÑ ½Ã°£ÀÌ µÇ¾ú´Ù.



Thyroid Cancer Survivorship Care ¼¼¼Ç¿¡¼­´Â °©»ó¼±¾ÏÀÇ ¼ö¼ú ÈÄ ¸ð´ÏÅ͸µ°ú µ¿¹ÝÁúȯ, QoL °ü¸®¿¡ À̸£±â±îÁö ÃֽŠ¿¬±¸°á°ú¿Í Ä¡·á Æ®·»µå¿¡ °üÇÑ °­¿¬ÀÌ ÀÖ¾úÀ¸¸ç Up-to date of Hyperthyroidism Management ¼¼¼Ç¿¡¼­´Â °©»ó¼±±â´ÉÇ×ÁøÁõÀÇ ¾à¹°, ¼ö¼ú, ¹æ»ç¼º¿ä¿ÀµåÄ¡·á µîÀÇ ÃֽŠÀ̽´¿¡ °üÇÑ Àü¹®°¡ °­ÀÇ°¡ À̾îÁ³´Ù.

ÃÑȸ¿¡¼­´Â ¼º±Õ°üÀÇ´ë ¿Ü°ú ±èÁö¼ö ±³¼ö°¡ 2025³â ȸÀåÀ¸·Î Ãß´ëµÇ¾úÀ¸¸ç À̾îÁö´Â Presidential Lecture¿¡¼­ Challenging Issues Toward a Unified Ultrasound Risk Stratification System for Thyroid Nodules¶ó´Â ÁÖÁ¦·Î 2024³â ³ªµ¿±Ô (¿ï»êÀÇ´ë ¿µ»óÀÇÇаú) ȸÀåÀÇ °­¿¬ÀÌ ÀÖ¾ú´Ù.



À̾îÁö´Â ¿ÀÈÄ ½Ã°£¿¡´Â US Guided Interventional Management of Benign Thyroid and Neck Lesions ¼¼¼Ç¿¡¼­ ÃÖ±Ù °ü½ÉÀÌ Áõ°¡ÇÏ°í ÀÖ´Â °©»ó¼±Á¾¾çÀÇ ºñ¼ö¼úÀû Ä¡·á¿¡ ´ëÇÑ ´Ù°¢µµÀÇ °­¿¬ÀÌ ÀÖ¾úÀ¸¸ç Áø·áÁöħÁ¦Á¤À§¿øȸ ¼¼¼ÇÀº ¡°KTA Áø·á±Ç°í¾ÈÀÇ ½ÇÁ¦ ÀÓ»ó Àû¿ë¡±À̶ó´Â ÁÖÁ¦·Î ½ÇÁ¦ Áõ·Ê¿¡ °üÇÑ Ã»Áß ÅõÇ¥¸¦ ÁøÇàÇÏ¿© Èï¹Ì¸¦ ²ø¾ú´Ù. KTA Á¤Ã¥ ¿¬±¸ °úÁ¦: °©»ó¼± °áÀý ¼±º°°Ë»ç¿¡ ´ëÇÑ È¿¿ë¼º ¿¬±¸ ¼¼¼Ç¿¡¼­´Â ÁÖ¿ä ÀïÁ¡ÀÌ µÇ°í ÀÖ´Â Key Questionº°·Î ±Ù°Å Á᫐ ¿¬±¸ °á°ú¸¦ ¹ÙÅÁÀ¸·Î ½Éµµ ÀÖ´Â ³íÀÇ°¡ ÁøÇàµÇ¾ú´Ù.

ÀÌ¿Í ÇÔ²² ÀÇÁ¤»çÅ·Π¾î·Á¿î ȯ°æ¿¡¼­µµ Free Paper ¼¼¼Ç¿¡ ¸¹Àº ȸ¿øµéÀÇ ÃÖ±Ù ¿¬±¸ °á°ú°¡ ¹ßÇ¥ µÇ¾î Å« °ü½É°ú Åä·ÐÀÇ ±âȸ°¡ ÀÖ¾ú´Ù.


<´ëÇÑ°©»ó¼±ÇÐȸ 2024 Ãß°èÇмú´ëȸ ¼ö»ó ³»¿ª>

±¸ºÐ ¿¬±¸ Á¦¸ñ ¼º¸í ¼Ò¼Ó
¿ì¼ö ¿¬±¸ÀÚ»ó Development of technology to predict progression of papillary thyroid microcarcinoma using mitochondrial DNA Á¶¿µ¼® ¿¬¼¼ÀÇ´ë ³»°ú
ÀþÀº ¿¬±¸ÀÚ»ó Analysis of Oral and Gut microbiomes Changes according to Hashimoto Thyroiditis following Thyroidectomy ±èÈñÁØ Â÷ÀÇ°ú´ë ¿Ü°ú
±âÃÊÀÇÇבּ¸»ó A Role of CHI3L1 in Orbital Fibroblast of Thyroid Eye Disease ÀÓµ¿ÁØ °¡Å縯ÀÇ´ë ³»°ú
Discovery of new therapies targeting the resistant mechanism of dabrafenib/trametinib combination treatment in thyroid cancer Àü¹ÎÁö ¿ï»êÀÇ´ë ³»°ú
ÃÖ¿ì¼ö³í¹®»ó ¿©´ü °¡Áö ½Ã¾àÀ¸·Î ÃøÁ¤ÇÑ Ç÷û °©»ó¼±ÀÚ±ØÈ£¸£¸ó °á°ú°ª Â÷ÀÌ: ¹«Áõ»ó°©»ó¼±±â´ÉÀúÇÏÁõ Áø·áÁöħÀÇ ÀÓ»ó Àû¿ëÀ» À§ÇÑ Âü°í±¸°£ ºñ±³ ¿¬±¸ À¯¿ø»ó,
±è¼ÖÀÙ/
Á¤Çö°æ, ÆØÁøö
´Ü±¹ÀÇ´ë ³»°ú,
¿ï»êÀÇ´ë Áø´Ü°Ë»çÀÇÇаú/
´Ü±¹ÀÇ´ë ³»°ú, ¼­¿ïÀÇ´ë ÇÙÀÇÇаú
The Role of De novo Serine Biosynthesis from Glucose in Papillary Thyroid Cancer À̼ºÀº/
°­¿¹Àº, ±¸º»¼®
Ãæ³²ÀÇ´ë/
Ãæ³²ÀÇ´ë ³»°ú, À̺ñÀÎÈÄ°ú
¿ì¼ö³í¹®»ó Artificial Intelligence Computer-Assisted Diagnosis for Thyroid Nodules: Comparison of Diagnostic Performance Using Original and Mobile Ultrasonography Images Á¶»ó¿ì/°ûÁø¿µ ¿¬¼¼ÀÇ´ë/¿¬¼¼ÀÇ´ë ¿µ»óÀÇÇаú
Effects of Isthmus Preservation on Postoperative Hypothyroidism after Lobectomy Àü¿µ»ê/±è¿Ï¿í ±¸º´¿ø ¿Ü°ú/»ïÀϺ´¿ø ¿Ü°ú
±¹Á¦ÇÐȸ³í¹®»ó BRAF mutation is associated with tumor volume doubling time of papillary thyroid microcarcinoma during active surveillance ±èÁø¿µ °¡Å縯ÀÇ´ë ³»°ú
Clinical Practice Guidelines for Radiofrequency Ablation of Benign Thyroid Nodules and Malignant Thyroid Cancers: A Systematic Review ÀÌ¹Î°æ °¡Å縯ÀÇ´ë ¿µ»óÀÇÇаú
Impact of additional computed tomography in patients with low-risk papillary thyroid microcarcinoma eligible for active surveillance Àü¿µÈÆ ¼­¿ïÀÇ´ë ¿µ»óÀÇÇаú
Serum anti-thyroglobulin antibody levels following total thyroidectomy are related to the recurrence of papillary thyroid carcinoma ÀÌÁؼº ¿¬¼¼ÀÇ´ë ¿Ü°ú
Comparative Outcomes of Synchronous Follicular and Papillary Thyroid Cancers: A Retrospective Analysis ±è³²°æ ¿¬¼¼ÀÇ´ë ¿Ü°ú
ÃÖ¿ì¼ö¿¬Á¦»ó Deep Learning Model for Preoperative Prediction of Lymph Node Metastasis in Thyroid Cancer Using Whole Slide Images of Core Needle Biopsies Á¤Âù±Ç °¡Å縯ÀÇ´ë º´¸®°ú
¿ì¼ö¿¬Á¦»ó Impact of additional computed tomography in patients with low-risk papillary thyroid microcarcinoma eligible for active surveillance Àü¿µÈÆ ¼­¿ïÀÇ´ë ¿µ»óÀÇÇаú
Early Detection of Medullary Thyroid Carcinoma for Improving Initial Response and Long-Term Survival À¯ÁöÇö ¼º±Õ°üÀÇ´ë ³»°ú
INITIAL EXPERIENCE OF SINGLE-PORT TRANSAXILLARY ROBOTIC RADICAL NECK DISSECTION(STAR-RND) VIA 3CM INCISION ±èÁø°æ ¿¬¼¼ÀÇ´ë ¿Ü°ú
Diagnosis and evaluation of aggressiveness using circulating plasma miRNAs in papillary thyroid microcarcinoma À̺´ÁÖ ºÎ»êÀÇ´ë À̺ñÀÎÈÄ°ú
Impact of fibroblast growth factor receptor (FGFR) inhibition for reinforcing radioactive-iodine (RAI) avidity in thyroid cancers ¾Èº´Ã¶ °æºÏÀÇ´ë ÇÙÀÇÇаú
¿ì¼öÆ÷½ºÅÍ»ó A Prospective Clinical Trial of Radiofrequency Ablation in Patients with Low-Risk Unifocal Papillary Thyroid Microcarcinoma favoring Active Surveillance over Surgery ÀÌÁö¿¹ ¼­¿ïÀÇ´ë ¿µ»óÀÇÇаú
Unveiling the Impact of BRAFV600E Mutation on Nuclear Invagination via High-Resolution Digital Microscopy ÀÌÇÏ¿µ ±¹¸³¾Ï¼¾ÅÍ